Tags

Type your tag names separated by a space and hit enter

Role of prostacyclin in the cardiovascular response to thromboxane A2.
Science. 2002 Apr 19; 296(5567):539-41.Sci

Abstract

Thromboxane (Tx) A2 is a vasoconstrictor and platelet agonist. Aspirin affords cardioprotection through inhibition of TxA2 formation by platelet cyclooxygenase (COX-1). Prostacyclin (PGI2) is a vasodilator that inhibits platelet function. Here we show that injury-induced vascular proliferation and platelet activation are enhanced in mice that are genetically deficient in the PGI2 receptor (IP) but are depressed in mice genetically deficient in the TxA2 receptor (TP) or treated with a TP antagonist. The augmented response to vascular injury was abolished in mice deficient in both receptors. Thus, PGI2 modulates platelet-vascular interactions in vivo and specifically limits the response to TxA2. This interplay may help explain the adverse cardiovascular effects associated with selective COX-2 inhibitors, which, unlike aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), inhibit PGI2 but not TxA2.

Authors+Show Affiliations

Center for Experimental Therapeutics, 153 Johnson Pavilion, 3620 Hamilton Walk, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6084, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

11964481

Citation

Cheng, Yan, et al. "Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2." Science (New York, N.Y.), vol. 296, no. 5567, 2002, pp. 539-41.
Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296(5567):539-41.
Cheng, Y., Austin, S. C., Rocca, B., Koller, B. H., Coffman, T. M., Grosser, T., Lawson, J. A., & FitzGerald, G. A. (2002). Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (New York, N.Y.), 296(5567), 539-41.
Cheng Y, et al. Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2. Science. 2002 Apr 19;296(5567):539-41. PubMed PMID: 11964481.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of prostacyclin in the cardiovascular response to thromboxane A2. AU - Cheng,Yan, AU - Austin,Sandra C, AU - Rocca,Bianca, AU - Koller,Beverly H, AU - Coffman,Thomas M, AU - Grosser,Tilo, AU - Lawson,John A, AU - FitzGerald,Garret A, PY - 2002/4/20/pubmed PY - 2002/5/15/medline PY - 2002/4/20/entrez SP - 539 EP - 41 JF - Science (New York, N.Y.) JO - Science VL - 296 IS - 5567 N2 - Thromboxane (Tx) A2 is a vasoconstrictor and platelet agonist. Aspirin affords cardioprotection through inhibition of TxA2 formation by platelet cyclooxygenase (COX-1). Prostacyclin (PGI2) is a vasodilator that inhibits platelet function. Here we show that injury-induced vascular proliferation and platelet activation are enhanced in mice that are genetically deficient in the PGI2 receptor (IP) but are depressed in mice genetically deficient in the TxA2 receptor (TP) or treated with a TP antagonist. The augmented response to vascular injury was abolished in mice deficient in both receptors. Thus, PGI2 modulates platelet-vascular interactions in vivo and specifically limits the response to TxA2. This interplay may help explain the adverse cardiovascular effects associated with selective COX-2 inhibitors, which, unlike aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), inhibit PGI2 but not TxA2. SN - 1095-9203 UR - https://www.unboundmedicine.com/medline/citation/11964481/Role_of_prostacyclin_in_the_cardiovascular_response_to_thromboxane_A2_ L2 - https://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=11964481 DB - PRIME DP - Unbound Medicine ER -